CoChat

Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial

Open access
Antonsen, Kerstin K, Klausen, Mette K, Brunchmann, Amanda S, le Dous, Nina, Jensen, Mathias E, Miskowiak, Kamilla Woznica, Fisher, Patrick M, Thomsen, Gerda K, Rindom, Henrik, Fahmy, Thomas P, Vollstaedt-Klein, Sabine, Benveniste, Helene, Volkow, Nora D, Becker, Ulrik, Ekstrøm, Claus, Knudsen, Gitte Moos, Vilsbøll, Tina, Fink-Jensen, Anders · 2018 · BMJ Open
Cited by 47

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Introduction: Alcohol dependence is a major public health problem. It is underdiagnosed and undertreated. Even when treated, more than 2/3 of patients in abstinence-oriented treatment will relapse within the first year. Thus, there is an urgent need for efficacious medical treatment of alcohol dependence. Glucagon-like peptide-1 (GLP-1) receptor stimulation has proven to reduce alcohol consumption in preclinical experiments. However, the effect of GLP-1 receptor agonists in humans has to our knowledge, not yet been investigated. Methods and analysis: Design, participants and intervention : The effect of the once-weekly GLP-1-receptor-agonist exenatide will be investigated in a double-blinded, placebo-controlled, randomised clinical trial. 114 outpatients will be recruited and randomised to treatment with either placebo or exenatide once weekly for 26 weeks as a supplement to cognitive–behavioural therapy. The primary endpoint is reduction in number of ‘heavy drinking days’. The secondary endpoints include changes in total alcohol consumption, days without consumption, changes in brain activity and function, smoking status, cognition, measures of quality of life and changes in phosphatidylethanol as a biomarker of alcohol consumption from baseline to follow-up at week 26. Status : Currently recruiting patients. Ethics and dissemination: Ethical approval has been obtained. Before screening, all patients will be provided oral and written information about the trial. The study results will be disseminated by peer-review publications and conference presentations and has the potential to reveal a completely new medical treatment of alcohol dependence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2017-019562

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 47

Metadata

Authors
Antonsen, K. K., Klausen, M. K., Brunchmann, A. S., le Dous, N., Jensen, M. E., Miskowiak, K. W., Fisher, P. M., Thomsen, G. K., Rindom, H., Fahmy, T. P., Vollstaedt-Klein, S., Benveniste, H., Volkow, N. D., Becker, U., Ekstrøm, C., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A.
Venue
BMJ Open
Publisher
BMJ
Published
2018-07
Volume
8
Issue
7
Pages
e019562
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2884458055
Cited by
47
References
14
FWCI
2.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1136/bmjopen-2017-019562
The paper
Antonsen, K. K., Klausen, M. K., Brunchmann, A. S., le Dous, N., Jensen, M. E., Miskowiak, K. W., Fisher, P. M., Thomsen, G. K., Rindom, H., Fahmy, T. P., Vollstaedt-Klein, S., Benveniste, H., Volkow, N. D., Becker, U., Ekstrøm, C., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (2018). Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open. https://doi.org/10.1136/bmjopen-2017-019562

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.